As we observed congruence between ULBP1 mRNA and protein expression, we expect that the activity of NKG2DL regulating pathways is altered upon treatment with TMZ and niraparib in GBM to upregulate ULBP1 and the resulting protein expression. This evidence concerns the gene ULBP1 and glioblastoma.